GSK's Tesaro Sues AnaptysBio Over Jemperli License Dispute

GSK's Tesaro unit has sued AnaptysBio in Delaware Chancery Court alleging a material breach of their 2014 license for oncology drug Jemperli (dostarlimab), seeking the right to terminate the license, secure a perpetual, irrevocable licence and cut related royalties and milestone payments by 50%; GSK and Tesaro say AnaptysBio's contrary claims that Tesaro failed contractual obligations are without merit. The litigation risks altering the economics and commercialization pathway for a drug approved in 35+ countries and driving a broad clinical program in additional cancers, so the outcome could materially affect future royalty streams and strategic control of dostarlimab. GSK shares ticked down about 0.5% to $46.11 while AnaptysBio traded in the mid-$30s, closing Nov. 20 at $37.66.

Analysis

GSK's Tesaro unit has filed suit in Delaware Chancery against AnaptysBio alleging a material breach of their 2014 license for Jemperli (dostarlimab), seeking rights to terminate the license, obtain a perpetual irrevocable license and cut related royalties and milestone payments by 50 percent; AnaptysBio has asserted Tesaro failed to meet contractual obligations and threatened revocation, which GSK and Tesaro call without merit. Jemperli is approved in more than 35 countries and the article cites strong growth driven by recent U.S. and EU label expansions, while GSK says it continues a broad clinical program in rectal, colon and head-and-neck cancers, underlining the commercial and pipeline value at stake. Market reaction in the article is muted-to-volatile: GSK shares closed down 0.50% at $46.11, AnaptysBio closed Nov. 20 at $37.66 (up 1.76%) with overnight prints around $36.43, reflecting short-term uncertainty; aggregated signals rate overall sentiment as moderately negative with especially negative sentiment for ANAB and a modest market-impact score (0.34). The dispute creates a binary, event-driven risk to future royalty streams, milestone receipts and strategic control of dostarlimab; the Delaware forum and the contract terms will likely determine timing and magnitude of any valuation impact, while ongoing clinical work reduces immediate operational disruption risk.

Key Decisions for Investors

• Consider holding or selectively accumulating GSK on measured weakness while monitoring court filings and company disclosures because a Tesaro win could improve long-term economics,
• Avoid initiating or add exposure to AnaptysBio until material legal clarity is provided given negative sentiment, share-price volatility and potential royalty/milestone dilution,
• Monitor near-term catalysts closely (Delaware Chancery motions, injunctive relief requests, formal discovery outcomes and commercial revenue updates for Jemperli) and size positions accordingly,
• Use event-driven hedges (protective puts or collars) rather than pure directional bets because litigation outcomes are binary and can take months to resolve